Effect of antihypertensive medications on the risk of open-angle glaucoma

Jihei Sara Lee1, Hye Ryeong Cha2, Hyoung Won Bae1

  • 1Department of Ophthalmology, Severance Hospital, Institute of Vision Research, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea.

Scientific Reports
|September 27, 2023
PubMed

Insights

Certain blood pressure medications, specifically angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs), may slightly increase open-angle glaucoma (OAG) risk in hypertensive patients. Further research is needed to clarify these associations.

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Cardiology

Background:

  • Hypertension (HTN) is a prevalent condition often managed with antihypertensive medications.
  • Open-angle glaucoma (OAG) is a leading cause of irreversible blindness.
  • The potential impact of antihypertensive therapies on OAG risk remains an area of investigation.

Purpose of the Study:

  • To investigate the association between specific classes of antihypertensive medications and the risk of developing open-angle glaucoma (OAG) in patients with hypertension (HTN).

Main Methods:

  • A retrospective cohort study involving 5,195 patients diagnosed with HTN and subsequently OAG.
  • Matched controls (n=25,975) were selected based on hypertension diagnosis date, residential area, insurance, and economic status.
  • Antihypertensive medications were categorized into five types: ACE inhibitors, ARBs, CCBs, beta-blockers, and diuretics. Relative risks were calculated after adjusting for multiple confounding factors.

Main Results:

  • Angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) were associated with a slight increase in OAG risk (RR 1.1087 and 1.0694, respectively).
  • Combinations of ARBs with diuretics and CCBs also showed a modest increase in OAG risk.
  • Overall, antihypertensive medication use demonstrated a small increase in OAG risk.

Conclusions:

  • Antihypertensive medications, particularly ARBs and CCBs, may be associated with a small but statistically significant increase in the risk of open-angle glaucoma.
  • Further research is warranted to elucidate the complex interplay between blood pressure, medication effects, and OAG development.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
474
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
555
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
614
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
771
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
683
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
804